154 related articles for article (PubMed ID: 27085459)
1. CACUL1 functions as a negative regulator of androgen receptor in prostate cancer cells.
Choi H; Lee SH; Um SJ; Kim EJ
Cancer Lett; 2016 Jul; 376(2):360-6. PubMed ID: 27085459
[TBL] [Abstract][Full Text] [Related]
2. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer.
Hoang DT; Gu L; Liao Z; Shen F; Talati PG; Koptyra M; Tan SH; Ellsworth E; Gupta S; Montie H; Dagvadorj A; Savolainen S; Leiby B; Mirtti T; Merry DE; Nevalainen MT
Mol Cancer Ther; 2015 Mar; 14(3):713-26. PubMed ID: 25552366
[TBL] [Abstract][Full Text] [Related]
5. ACSL4 promotes prostate cancer growth, invasion and hormonal resistance.
Wu X; Deng F; Li Y; Daniels G; Du X; Ren Q; Wang J; Wang LH; Yang Y; Zhang V; Zhang D; Ye F; Melamed J; Monaco ME; Lee P
Oncotarget; 2015 Dec; 6(42):44849-63. PubMed ID: 26636648
[TBL] [Abstract][Full Text] [Related]
6. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
[TBL] [Abstract][Full Text] [Related]
7. FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer.
Jones D; Wade M; Nakjang S; Chaytor L; Grey J; Robson CN; Gaughan L
Oncotarget; 2015 Oct; 6(30):29782-94. PubMed ID: 26336819
[TBL] [Abstract][Full Text] [Related]
8. A novel androgen receptor-binding element modulates Cdc6 transcription in prostate cancer cells during cell-cycle progression.
Jin F; Fondell JD
Nucleic Acids Res; 2009 Aug; 37(14):4826-38. PubMed ID: 19520769
[TBL] [Abstract][Full Text] [Related]
9. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor-mediated repression of novel target genes.
Prescott J; Jariwala U; Jia L; Cogan JP; Barski A; Pregizer S; Shen HC; Arasheben A; Neilson JJ; Frenkel B; Coetzee GA
Prostate; 2007 Sep; 67(13):1371-83. PubMed ID: 17624924
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of lysine-specific demethylase 1 promotes androgen-independent transition of human prostate cancer LNCaP cells through activation of the AR signaling pathway and suppression of the p53 signaling pathway.
Li X; Li T; Chen D; Zhang P; Song Y; Zhu H; Xiao Y; Xing Y
Oncol Rep; 2016 Jan; 35(1):584-92. PubMed ID: 26534764
[TBL] [Abstract][Full Text] [Related]
12. PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.
Gravina GL; Marampon F; Muzi P; Mancini A; Piccolella M; Negri-Cesi P; Motta M; Lenzi A; Di Cesare E; Tombolini V; Jannini EA; Festuccia C
Endocr Relat Cancer; 2013 Jun; 20(3):321-37. PubMed ID: 23507703
[TBL] [Abstract][Full Text] [Related]
13. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor.
Kang Z; Jänne OA; Palvimo JJ
Mol Endocrinol; 2004 Nov; 18(11):2633-48. PubMed ID: 15308689
[TBL] [Abstract][Full Text] [Related]
14. HEXIM1 plays a critical role in the inhibition of the androgen receptor by anti-androgens.
Yeh IJ; Song K; Wittmann BM; Bai X; Danielpour D; Montano MM
Biochem J; 2014 Sep; 462(2):315-27. PubMed ID: 24844355
[TBL] [Abstract][Full Text] [Related]
15. CX4945 suppresses the growth of castration-resistant prostate cancer cells by reducing AR-V7 expression.
Deng C; Chen J; Guo S; Wang Y; Zhou Q; Li Z; Yang X; Yu X; Zhang Z; Zhou F; Han H; Yao K
World J Urol; 2017 Aug; 35(8):1213-1221. PubMed ID: 28105499
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation‑induced OPHN1 amplification promotes castration‑resistant prostate cancer.
Liu J; Zhang Y; Li S; Sun F; Wang G; Wei D; Yang T; Gu S
Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34738630
[TBL] [Abstract][Full Text] [Related]
17. CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.
Khanna A; Rane JK; Kivinummi KK; Urbanucci A; Helenius MA; Tolonen TT; Saramäki OR; Latonen L; Manni V; Pimanda JE; Maitland NJ; Westermarck J; Visakorpi T
Oncotarget; 2015 Aug; 6(23):19661-70. PubMed ID: 25965834
[TBL] [Abstract][Full Text] [Related]
18. Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy.
O'Neill D; Jones D; Wade M; Grey J; Nakjang S; Guo W; Cork D; Davies BR; Wedge SR; Robson CN; Gaughan L
Oncotarget; 2015 Sep; 6(28):26029-40. PubMed ID: 26267320
[TBL] [Abstract][Full Text] [Related]
19. Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures.
Chattopadhyay I; Wang J; Qin M; Gao L; Holtz R; Vessella RL; Leach RW; Gelman IH
Oncotarget; 2017 Feb; 8(6):10324-10347. PubMed ID: 28055971
[TBL] [Abstract][Full Text] [Related]
20. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]